WO2022248547A1 - Compositions contenant des substances formant membrane pour la production d'une mousse formée par pompage - Google Patents

Compositions contenant des substances formant membrane pour la production d'une mousse formée par pompage Download PDF

Info

Publication number
WO2022248547A1
WO2022248547A1 PCT/EP2022/064197 EP2022064197W WO2022248547A1 WO 2022248547 A1 WO2022248547 A1 WO 2022248547A1 EP 2022064197 W EP2022064197 W EP 2022064197W WO 2022248547 A1 WO2022248547 A1 WO 2022248547A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation according
foam
membrane
glycol
formulation
Prior art date
Application number
PCT/EP2022/064197
Other languages
German (de)
English (en)
Inventor
Rolf Daniels
Original Assignee
Prof4Skin Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prof4Skin Gmbh filed Critical Prof4Skin Gmbh
Priority to EP22731523.1A priority Critical patent/EP4346770A1/fr
Publication of WO2022248547A1 publication Critical patent/WO2022248547A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to cosmetic and dermatological foam formulations based on emulsions, in particular of the oil-in-water type, the oil phase comprising at least one membrane-forming substance which forms a lamellar membrane in the formulation, the formulation for foaming with a propellant-free, mechanical pump head.
  • Formulations are known from EP 2020221 B1 which can be foamed and used for cosmetic and/or dermatological applications.
  • the formulations mentioned there contain membrane-forming substances which also form a lamellar membrane in a foam formulation.
  • the formulations described there can be used as carriers for active ingredients, as mildew care products or mildew cleaning agents.
  • the formulations described can also be foamed using propellant gases.
  • compositions according to claim 1 of the present patent application are outstandingly suitable for fulfilling the above-mentioned objects.
  • oil-in-water emulsions formed by an oil phase and a water phase, the oil phase comprising at least one membrane-forming substance which forms a lamellar membrane arranged in the foam formulation, characterized by a proportion of 0.5- 5% by weight of one or more special foam surfactants, selected from the alkylpolyglucosides and/or alkylamidobetaines, in particular decyl glucoside and/or cocoamidopropylbetaine, are excellently suited for foaming without propellant using a mechanical foam pump head.
  • the formulations according to the invention also optionally contain 0.25-2.5% by weight of a polymeric thickener or gelling agent or a mixture, such as xanthan gum, acacia gum, microcrystalline cellulose and/or Sphingomonas ferment extract. Xanthan gum and/or acacia gum are preferred here. You can also optionally contain 0.25-1.5% by weight of Phospholipon 80H and/or Phospholipon 90H.
  • Particularly suitable foams have been obtained by further using 0.25-2.5% by weight of xanthan gum and/or acacia gum.
  • Formulations that contain both decyl glucoside and/or cocoamidopropyl betaine and xanthan gum and/or acacia gum are therefore particularly preferred embodiments of the invention.
  • formulations according to the invention for foam stabilization can also contain hydrogenated phospholipids, in particular Phospholipon 80H and/or Phospholipon 90H.
  • the ratio of foaming surfactant to hydrogenated phospholipid is preferably between 1:0.5 and 1:5.
  • the formulations according to the invention have the particular advantage of not requiring any PEG derivatives and any sulfates or sulfonates. Furthermore, the formulation does not require any liquid plastics, such as e.g. B. polyacrylic acid and its derivatives.
  • the formulations according to the invention are preferably provided in propellant-free containers and removed by means of a mechanical pump head, the pump head being set up to foam the formulation.
  • Such pump heads are known from the prior art and are available in bulk (e.g. Frapak foam pump type M3, Frapak foam pump type F2, pack tech PTY-FOAM-FLEUR, packtech PTY-FOAM-OLAYA, Quadpack 3 mesh Foamer).
  • the formulations according to the invention are suitable in the same way when using electrically driven, mechanical foam pumps that work without propellants.
  • Such pumps e.g. touch-free foam dispensers from the companies VEEAPE or Farsaw
  • VEEAPE touch-free foam dispensers from the companies VEEAPE or Farsaw
  • these foam dispensers too, there was the difficulty of producing a foamable preparation according to the invention with membrane-forming substances that can produce a foam without using a blowing agent.
  • a membrane-forming substance that forms a lamellar membrane is a substance that has both a hydrophilic and a hydrophobic moiety at the same time.
  • Substances such as (mono-, di-, tri-)glycerides, lecithins, sphingolipids, phospholipids, ceramides, cholesterol, squalene, squalane, fatty alcohols, fatty acids and their mono- and/or diesters, sterols, etc. are preferred.
  • a lamellar membrane is arranged in such a way that it has a layer structure such that the respective upper layer of the substance is aligned with a lower layer of the substance.
  • the alignment of the individual substance layers relative to one another takes place independently of the solvent used in such a way that, for example, the hydrophilic residues of the substance point outwards and the hydrophobic residues face inwards, or vice versa.
  • the membrane can be in the form of a single membrane, a double membrane or a multiple membrane.
  • body-identical fats are fats found in the body of plant origin.
  • the membrane-forming substance is present in a lamellar structure in a mixture with skin-related lipids such as free fatty acids, triglycerides (e.g. medium-chain triglycerides), squalane or squalene, ceramides (e.g. ceramide-3, sphingolipids and cholesterol and cholesterol esters.
  • skin-related lipids such as free fatty acids, triglycerides (e.g. medium-chain triglycerides), squalane or squalene, ceramides (e.g. ceramide-3, sphingolipids and cholesterol and cholesterol esters.
  • the membrane-forming substance or the membrane-forming lipid mixture is used in an amount of 0.2 to 20%, preferably 1 to 10%, particularly preferably 2 to 5%.
  • Suitable components which can form the oil phase can be chosen from polar and non-polar oils or mixtures thereof.
  • the oil phase of the formulations according to the invention is advantageously chosen from the group of lecithins, (mono-, di-, tri-)glycerides (such as the fatty acid triglycerides), sphingolipids, phospholipids, from the group of propylene glycols or butylene glycols, fatty acid esters, from the Group of natural waxes of animal and vegetable origin, from the group of ester oils, from the group of dialkyl ethers and dialkyl carbonates, from the group of branched and unbranched hydrocarbons and waxes, and from the group of cyclic and linear silicone oils.
  • lecithins (mono-, di-, tri-)glycerides (such as the fatty acid triglycerides), sphingolipids, phospholipids, from the group of propylene glycols or butylene glycols, fatty acid esters, from the Group of natural waxes of animal and vegetable origin, from the group of ester oils
  • the foam formulations according to the present invention enable an improved care effect of the formulation. Due to the analog structure of the lamellar structure of the skin, an easier integration of the membrane into the skin is achieved. The integration leads also to an improvement, in particular the stabilization and restoration of the skin barrier. An intact skin barrier protects the skin from excessive moisture loss. An improvement in the skin barrier can also bring about improved smoothing of the skin and reduce the "wash-out" effect, as a result of which a better long-term effect is advantageously achieved in comparison to conventional foam formulations.
  • Preferred foam formulations of the present invention utilize membrane-forming biomimetic lipids or lipid mixtures. These are "skin-like" ingredients to create the resemblance of the lamellar membrane present in the foam formulation to skin. Particularly preferred embodiments replace e.g. the natural glycerides present in the horny layer (the skin mainly contains a mixture of di- and triglycerides) with e.g. (vegetable) triglycerides, squalene with e.g. the less oxidation-sensitive squalane, ceramides with ceramide 3 (from yeast ), cholesterol replaced by (plant) phytosterols and phospholipids by (plant) phospholipids.
  • the membrane-forming, biomimetic lipids or lipid mixtures are present in the emulsion in an amount of 0.2 to 20%, preferably 1 to 10%, particularly preferably 2 to 5%.
  • the membrane-forming substance comprises a lipid, more preferably a triglyceride and/or lecithin.
  • the triglyceride is caprylic/capric acid triglyceride and/or the lecithin is hydrogenated lecithin.
  • the formulation may further comprise lecithin, preferably hydrogenated lecithin.
  • the preferred foam formulations according to the invention can also contain other components such as stabilizers such as alcohols or glycols.
  • stabilizers such as alcohols or glycols.
  • Glycols are preferred, in particular pentylene glycol, hexylene glycol and caprylyl glycol or mixtures thereof.
  • foam formulations of the invention further ingredients such as Butyrospermum Parkii (shea butter), squalane, glycerides, ceramides, preferably ceramide 3 or mixtures of the aforementioned may comprise.
  • Butyrospermum Parkii shea butter
  • squalane glycerides
  • ceramides preferably ceramide 3 or mixtures of the aforementioned may comprise.
  • Base creams that make use of the biomimetic, ie "skin-like" ingredients described above are also known in the art as DMS® or SLM® or SLM® base creams.
  • the DMS ® or SLM ® base compositions may contain the following ingredients: caprylic acid/capric acid triglyceride, shea butter, squalane, ceramide 3, hydrogenated lecithin, palm glyceride, Persea gratissima, palm oil (Elaesis Guineensis).
  • Alcohols or glycols such as pentylene glycol, hexylene glycol, octylene glycol, caprylyl glycol or mixtures thereof can be used as stabilizers in the DMS® or SLM® compositions.
  • a commercially available DMS® or SLM® base includes caprylic acid/capric acid triglyceride, shea butter, squalane, ceramide 3, hydrogenated lecithin and pentylene glycol.
  • DMS® or SLM® base includes caprylic acid/capric acid triglyceride, shea butter, squalane, ceramide 3, hydrogenated lecithin and alcohol.
  • DMS® or SLM® base includes caprylic acid/capric acid triglyceride, shea butter, squalane, ceramide 3, hydrogenated lecithin,
  • Persea gratissima and caprylyl glycol Another commercially available DMS® or SLM® base includes caprylic acid/capric acid triglyceride, shea butter, squalane, ceramide 3, hydrogenated lecithin, palm glycerides, elaesis guineensis and pentylene glycol.
  • a preferred DMS® or SLM® base includes caprylic acid/capric acid triglyceride, butyrospermum parkii, squalane, ceramide 3, hydrogenated lecithin and pentylene glycol.
  • a particularly preferred triglyceride of caprylic acid/capric acid is available under the name Miglyol 812 from Sasol and its mixture with other oil and wax components.
  • caprylic acid/capric acid triglyceride available under the name Miglyol 812 from Sasol/Myritol 312 from BASF/Tegosoft CT from Evonik.
  • the emulsions according to the invention preferably contain from 5 to 50% by weight of oil phase, more preferably 10 to 35% by weight and most preferably 15 to 35% by weight of oil phase.
  • the data are in each case based on the total weight of the emulsion.
  • cream compositions are used in particular for irritated, dry to very dry, sensitive to very sensitive, allergic and eczemic skin.
  • oil phase can preferably contain other components such as fatty acids, in particular stearic acid, or oils such as Cetiol V.
  • the water phase can contain cosmetic auxiliaries, e.g. lower alcohols (e.g. ethanol, isopropanol), lower diols or polyols and their ethers (e.g. propylene glycol, glycerine, butylene glycol, hexylene glycol and ethylene glycol), foam stabilizers and thickeners.
  • cosmetic auxiliaries e.g. lower alcohols (e.g. ethanol, isopropanol), lower diols or polyols and their ethers (e.g. propylene glycol, glycerine, butylene glycol, hexylene glycol and ethylene glycol), foam stabilizers and thickeners.
  • Suitable thickeners are polymeric thickeners that are partially water soluble or at least water dispersible and form gels or viscous solutions in aqueous systems. They increase the viscosity of the water either by binding water molecules (hydration) or by absorbing and enveloping the water in their intertwined macromolecules, thereby restricting the mobility of the water.
  • polymers suitable as thickeners are:
  • cellulose ethers e.g. hydroxypropyl cellulose ether, hydroxyethyl cellulose and hydroxypropylmethyl cellulose ether
  • cellulose ethers e.g. hydroxypropyl cellulose ether, hydroxyethyl cellulose and hydroxypropylmethyl cellulose ether
  • Natural compounds such as agar-agar, carrageenan, polyoses, starch, dextrins, gelatin, casein;
  • a cellulose ether is included as a thickening agent in the formulation of the invention.
  • Hydroxypropylmethylcellulose is particularly preferred.
  • a preferred hydroxypropylmethylcellulose according to the invention is Metolose 90SH100.
  • xanthan gum e.g. B. Keltrol® CG or Rheocare XGN.
  • acacia gum or microcrystalline cellulose eg Sensocel stab 026 N or Sphingomonas Ferment Extract.
  • the hydroxypropylmethyl cellulose, xanthan gum and microcrystalline cellulose can also be used side by side in the formulation according to the invention.
  • the emulsions according to the invention preferably contain from 0.2 to 3.0% by weight of thickener (based on the dry weight of the thickener and the total weight of the emulsion without propellant gas). 0.5 to 2.5% by weight of thickener is particularly preferred.
  • the active substance contained can be selected from all active substances that can be applied to the surface of the skin and mixtures of these.
  • the active ingredient can act cosmetically or pharmaceutically.
  • cosmetic or dermatological foam formulations to be used as a medical product or pharmaceutical product.
  • the formulation can serve to protect the skin from environmental influences.
  • the active ingredient can be purely herbal or synthetic.
  • the group of active ingredients can also overlap with the other groups of ingredients, such as the oil component, the thickeners or the solid emulsifiers.
  • some oil components can also serve as active ingredients, such as oils with polyunsaturated fatty acids.
  • particulate active ingredients such as titanium dioxide
  • adapted solid emulsifiers can be added.
  • the substances can be assigned to several groups.
  • Active ingredients of the formulations according to the invention are advantageously selected from the group of substances with moisturizing and barrier-enhancing properties, such as. B. Hydroviton, a replica of the NMF, pyrrolidone carboxylic acid and its salts, lactic acid and its salts, glycerol, sorbitol, propylene glycol and urea, substances from the group of proteins and protein hydrolyzates such.
  • B. Hydroviton a replica of the NMF, pyrrolidone carboxylic acid and its salts, lactic acid and its salts, glycerol, sorbitol, propylene glycol and urea
  • substances from the group of proteins and protein hydrolyzates such.
  • collagen, elastin and silk protein substances from the group of glucosaminoglucans, such as. B. hyaluronic acid, from the group of carbohydrates such as B.
  • Pentavitin which corresponds in its composition to the carbohydrate mixture of the human horny layer, and the group of lipids and lipid precursors such as ceramides.
  • further advantageous active ingredients can also be selected from the group of vitamins, such as e.g. B. panthenol, niacin, a-tocopherol and its esters, vitamin A and vitamin C.
  • galates and polyphenols can be used. Urea, hyaluronic acid and pentavitin are preferred substances.
  • substances with skin-soothing and regenerating effects are used as active ingredients, such as e.g. B. panthenol, bisabolol and phytosterols.
  • Advantageous active ingredients for the purposes of the present invention are also plants and plant extracts. These include, for example, algae, aloe, arnica, beard lichen, comfrey, birch, nettle, calendula, oak, ivy, witch hazel, henna, hops, chamomile, butcher's broom, peppermint, marigold, rosemary, sage, green tea, tea tree, horsetail, and thyme Walnut and its extracts and birch bark extract.
  • algae aloe, arnica, beard lichen, comfrey, birch, nettle, calendula, oak, ivy, witch hazel, henna, hops, chamomile, butcher's broom, peppermint, marigold, rosemary, sage, green tea, tea tree, horsetail, and thyme Walnut and its extracts and birch bark extract.
  • the preparations according to the invention can also contain antimycotics and antiseptics/disinfectants of synthetic or natural origin as active ingredients.
  • active ingredients are glucocorticoids, antibiotics, analgesics, antiphlogistics, antirheumatics, antiallergics, antiparasitics, antipruritic drugs, antipsoriatics, retinoids, local anesthetics, vein therapeutics, keratolytics, hyperemic substances, coronary therapeutics (nitrates/nitro compounds), antivirals, cytostatics, hormones, active ingredients that promote wound healing, e.g. growth factors, enzyme preparations and insecticides.
  • the formulations can also optionally contain dyes, pearlescent pigments, fragrances/perfumes, preservatives, complexing agents, and antioxidants Contain repellents and pH regulators.
  • the foam formulations according to the invention can also contain other natural fats, such as e.g. B. shea butter, neutral oils, olive oil, squalane, ceramides and humectants, as are customary in the art.
  • the foam formulations of the present invention are provided by providing an emulsion, preferably of the oil-in-water type, and filling the emulsion into a suitable container such as a standard plastic, aluminum, glass or tin container.
  • a suitable container such as a standard plastic, aluminum, glass or tin container.
  • the emulsions according to the invention are prepared by a method which comprises the following steps: (1) providing an oil phase, optionally comprising at least one membrane-forming substance which forms a lamellar membrane in the formulation, (2) providing a water phase, (3) combining and homogenizing the two phases, (4) optionally adding at least one or at least one further membrane-forming substance, (5) optionally homogenizing in order to obtain an emulsion containing at least one membrane-forming substance in at least one of steps (1) or (4). is, which forms a lamellar membrane in the formulation.
  • the oil phase and the water phase are preferably each mixed and homogenized at a temperature in the range from about 40 to about 90°C, a temperature range from about 60 to about 80°C being particularly preferred, more preferably a temperature of about 70°C. Any means or method known in the art can be used for the homogenization.
  • the phases are preferably homogenized using a high-speed stirrer, a rotor-stator homogenizer or a high-pressure homogenizer.
  • the oil phase is stirred into the water phase and homogenized. If necessary, the emulsion is cooled to room temperature while stirring. In a particularly preferred method, a suitable amount of a DMS® or SLM® concentrate is added to this mixture and the concentrate is incorporated into the present emulsion.
  • the DMS® or SLM® concentrate can be added to the oil phase before homogenizing with the water phase or added to the mixture after the oil and water phases have been homogenized. It is preferred that the DMS® or SLM® concentrate is added to the mixture after the first homogenisation step and the mixture is homogenised.
  • the method advantageously comprises the following further steps: (6) providing an aqueous thickener solution (7) mixing the thickener solution with the emulsion
  • the foam formulations of the present invention can be used for all cosmetic and dermatological (as medicinal product or drug) purposes.
  • the formulations can be used as skin care products or skin cleansing products. They can also serve as carriers for active ingredients and be used in the medical dermatological field.
  • the formulations can be used to treat dry or irritated skin and to treat acne.
  • Example 1 Composition for preparing a foam for application to the scalp
  • Example 2 Composition for preparing a foam for use on irritated facial skin without using a lamellar concentrate
  • Example 3 Composition for making a foam for use on acne
  • Example 4 Composition for preparing a foam for application to dry skin I
  • Example 4 Preparation of an emulsion
  • compositions according to Examples 1 - 3 are converted into an emulsion as follows:
  • the oil phase is formed by mixing the components, for which purpose the components may be heated to 80°C while stirring.
  • the water phase is then formed by mixing the components and also heated to up to 80°C while stirring. It makes sense to bring both phases to the same temperature. Both phases are combined and homogenized (e.g. using a rotor-stator homogenizer or another common emulsifying machine, e.g. high pressure homogenizer etc.).
  • one or more other membrane-forming substances are added and homogenized again.
  • each of the compositions according to Examples 1-3 is filled into a 100ml standard plastic, aluminum, glass or tinplate can which is fitted with a standard pump foam head (e.g. Frapak foam pump type M3, Frapak foam pump type F2, pack tech PTY- FOAM-FLEUR, pack tech PTY-FOAM-OLAYA, Quadpack 3 mesh Foamer) is closed.
  • a standard pump foam head e.g. Frapak foam pump type M3, Frapak foam pump type F2, pack tech PTY- FOAM-FLEUR, pack tech PTY-FOAM-OLAYA, Quadpack 3 mesh Foamer
  • the foam can be applied to the skin very gently and almost without touching it and is distributed very evenly.
  • the foam can be generated by an electrically operated, propellant-free foam pump.
  • Example 6 Comparative example
  • compositions according to Examples 1 or 2 of EP 2020221 B1 are filled into a 100 ml standard plastic, aluminum, glass or tinplate can which is sealed with a standard pump foam head Frapak foam pump type M3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations de mousses cosmétiques et dermatologiques, à base d'émulsions, en particulier de type huile dans l'eau, la phase huileuse comprenant au moins une substance formant membrane qui forme dans la formulation une membrane disposée de manière lamellaire, la formulation convenant pour être mise sous forme de mousse au moyen d'une tête de formation de mousse par pompage mécanique sans agent d'expansion.
PCT/EP2022/064197 2021-05-25 2022-05-25 Compositions contenant des substances formant membrane pour la production d'une mousse formée par pompage WO2022248547A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22731523.1A EP4346770A1 (fr) 2021-05-25 2022-05-25 Compositions contenant des substances formant membrane pour la production d'une mousse formée par pompage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102021002698.5A DE102021002698A1 (de) 2021-05-25 2021-05-25 Zusammensetzungen enthaltend membranbildende Substanzen zur Herstellung eines Pumpschaumes
DE102021002698.5 2021-05-25

Publications (1)

Publication Number Publication Date
WO2022248547A1 true WO2022248547A1 (fr) 2022-12-01

Family

ID=82115542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/064197 WO2022248547A1 (fr) 2021-05-25 2022-05-25 Compositions contenant des substances formant membrane pour la production d'une mousse formée par pompage

Country Status (3)

Country Link
EP (1) EP4346770A1 (fr)
DE (1) DE102021002698A1 (fr)
WO (1) WO2022248547A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1496852B1 (fr) 2002-04-19 2007-10-10 Cognis IP Management GmbH Emulsion de protection solaire et distributeur de mousse
ES2308654T3 (es) * 2005-03-25 2008-12-01 L'oreal Emulsion de aceite-en-agua espumante y su utilizacion cosmetica.
WO2010060896A1 (fr) * 2008-11-27 2010-06-03 Henkel Ag & Co. Kgaa Émulsions moussantes contenant une association d'émulsifiants
EP1388338B1 (fr) * 2002-08-07 2010-09-29 Beiersdorf AG Compositions anti-solaires moussables
WO2011012395A2 (fr) * 2009-07-31 2011-02-03 Evonik Stockhausen Gmbh Émulsion huile dans l'eau apte au moussage
EP2020221B1 (fr) 2007-06-19 2012-02-29 Neubourg Skin Care GmbH & Co. KG DMS (Derma Membrane Structure) dans des crèmes moussantes
WO2014076136A1 (fr) * 2012-11-13 2014-05-22 Galderma S.A. Composition d'emulsion de lavage au bpo
US20160120803A1 (en) * 2013-06-17 2016-05-05 Contract Pharmaceuticals Limited Non-aerosol foams for topical administration
EP3329903A1 (fr) * 2016-12-02 2018-06-06 Beiersdorf AG Mousse cosmétique à base d'une émulsion huile dans eau contenant un produit d'estérification à la glycérine doté des trois acides gras identiques
US20210093724A1 (en) * 2019-09-30 2021-04-01 Concept Matrix Solutions Topical anti-acne composition

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1496852B1 (fr) 2002-04-19 2007-10-10 Cognis IP Management GmbH Emulsion de protection solaire et distributeur de mousse
EP1388338B1 (fr) * 2002-08-07 2010-09-29 Beiersdorf AG Compositions anti-solaires moussables
ES2308654T3 (es) * 2005-03-25 2008-12-01 L'oreal Emulsion de aceite-en-agua espumante y su utilizacion cosmetica.
EP2020221B1 (fr) 2007-06-19 2012-02-29 Neubourg Skin Care GmbH & Co. KG DMS (Derma Membrane Structure) dans des crèmes moussantes
WO2010060896A1 (fr) * 2008-11-27 2010-06-03 Henkel Ag & Co. Kgaa Émulsions moussantes contenant une association d'émulsifiants
WO2011012395A2 (fr) * 2009-07-31 2011-02-03 Evonik Stockhausen Gmbh Émulsion huile dans l'eau apte au moussage
WO2014076136A1 (fr) * 2012-11-13 2014-05-22 Galderma S.A. Composition d'emulsion de lavage au bpo
US20160120803A1 (en) * 2013-06-17 2016-05-05 Contract Pharmaceuticals Limited Non-aerosol foams for topical administration
EP3329903A1 (fr) * 2016-12-02 2018-06-06 Beiersdorf AG Mousse cosmétique à base d'une émulsion huile dans eau contenant un produit d'estérification à la glycérine doté des trois acides gras identiques
US20210093724A1 (en) * 2019-09-30 2021-04-01 Concept Matrix Solutions Topical anti-acne composition

Also Published As

Publication number Publication date
DE102021002698A1 (de) 2022-12-01
EP4346770A1 (fr) 2024-04-10

Similar Documents

Publication Publication Date Title
EP2020221B1 (fr) DMS (Derma Membrane Structure) dans des crèmes moussantes
EP1992323B1 (fr) Formulations mousseuses sans tensioactif
DE10058384B4 (de) Kosmetisches oder dermatologisches Mittel in Form eines cremigen Permanentschaums oder einer stabil aufgeschäumten Creme, deren Verwendung und Verfahren zur Herstellung des Mittels
EP2335675B1 (fr) Formules de mousse sans émulsifiant et stabilisées par polymères
EP2363108B1 (fr) Formulation d'une mousse contenant au moins un triterpénoïde
DE60105362T2 (de) Wässrige kosmetische gele
DE10304721B4 (de) System für eine selbstschäumende Haarkur oder Spülung
EP3033090A2 (fr) Suspension de particules de gel d'agarose dans l'eau solides de type crème en tant que produit cosmétique intermédiaire
KR20130051705A (ko) 유화 안정성이 우수한 수중유형 나노 에멀젼, 이의 제조방법 및 이를 포함하는 화장료 조성물
EP2701671B1 (fr) CONCENTRE D'UNE OW EMULSION, PROCES POUR SA FABRICATION ET& xA;PRODUIT DE BEAUTE POUR LA PEAU CONTENANT CE CONCENTRE
EP2313054A2 (fr) Mousse de soins cutanés
DE69912760T2 (de) Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln
EP1704897B1 (fr) Compositions cosmétiques moussables
EP1752137A2 (fr) Bases et compositions hydophiles ou ambiphiles
WO2022248547A1 (fr) Compositions contenant des substances formant membrane pour la production d'une mousse formée par pompage
DE10057767A1 (de) Deodorant- und Antitranspirantprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
DE202021103593U1 (de) Hautverträgliches, pflegendes und schützendes Mittel zum Auftragen auf die Haut

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22731523

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2022731523

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022731523

Country of ref document: EP

Effective date: 20240102